Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
Can you apply?
This grant is for research organizations and individual researchers seeking to conduct hematology research with NIH support. Eligible applicants include universities, medical schools, research institutions, hospitals, and investigators at all career stages who are affiliated with eligible institutions. The program supports investigator-initiated R01 research projects focused on hematology topics but explicitly excludes clinical trial studies. Applicants must have an active institutional affiliation and meet NIH citizenship/visa requirements. The grant supports research that advances understanding of blood disorders, hemostasis, and related hematologic conditions, with funding available across the United States and U.S. territories.
This grant is for research organizations and individual researchers seeking to conduct hematology research with NIH support. Eligible applicants include universities, medical schools, research institutions, hospitals, and investigators at all career stages who are affiliated with eligible institutions. The program supports investigator-initiated R01 research projects focused on hematology topics but explicitly excludes clinical trial studies. Applicants must have an active institutional affiliation and meet NIH citizenship/visa requirements. The grant supports research that advances understanding of blood disorders, hemostasis, and related hematologic conditions, with funding available across the United States and U.S. territories.
Program description
The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated annually through the NIH Guide to Grants and Contracts and hyperlinked to this NOFO.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Hospital
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Researcher (independent)
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Details
This grant is for research organizations and individual researchers seeking to conduct hematology research with NIH support. Eligible applicants include universities, medical schools, research institutions, hospitals, and investigators at all career stages who are affiliated with eligible institutions. The program supports investigator-initiated R01 research projects focused on hematology topics but explicitly excludes clinical trial studies. Applicants must have an active institutional affiliation and meet NIH citizenship/visa requirements. The grant supports research that advances understanding of blood disorders, hemostasis, and related hematologic conditions, with funding available across the United States and U.S. territories.
How to apply
Application links
Required documents
- SF-424 (R&R) application form
- Project Narrative (Research Strategy) - typically 12-15 pages
- Detailed Budget and Budget Justification
- Biosketch of Principal Investigator and key personnel (using current NIH format)
- Institutional Support Letter
- Timeline for research milestones
- Literature references
- Institutional Review Board (IRB) certification or determination if human subjects are involved
- Animal Care and Use Committee (IACUC) certification if animal research is proposed
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.839 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$22,197,349
-
$20,132,449
-
$18,556,003
-
$17,136,580
-
$16,771,574
-
$16,547,541
-
$14,584,323
-
$13,300,404
-
$13,270,012
-
$13,111,643
Top States by Funding
- MA 14 awards $127.2M
- PA 11 awards $98.8M
- CA 8 awards $84.2M
- NY 8 awards $77.5M
- MD 6 awards $55.7M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.839). How funding has trended year over year.
| 2024 | $431,558,338 | |
| 2025 | $425,332,322 |
FAQ
Who is eligible to apply for the SHINE R01 grant?
Researchers affiliated with eligible institutions including universities, medical schools, hospitals, and research centers can apply. Applicants must have a degree beyond the bachelor's level (or equivalent) and be sponsored by an eligible institution.
Are clinical trials allowed under this grant?
No. The R01 mechanism for SHINE explicitly excludes clinical trial studies. Research must be basic or translational science focused on hematology.
What is the deadline and how often is this program offered?
The deadline is typically fixed annually (check NIH website for current cycles). The SHINE program follows standard NIH R01 submission timelines with multiple submission windows per year.
What types of research activities are supported?
The program supports investigator-initiated research in hematology including basic research, translational research, and mechanistic studies of blood disorders, coagulation, immune hematology, and related topics.
What is the typical funding range?
NIH R01 awards typically range from $100,000 to $750,000 per year depending on the research scope and institutional indirect cost rates. Direct costs for hematology research typically average $200,000-$400,000 annually.
💡 Tips for applicants
- Ensure your research question is not a clinical trial. NIH defines clinical trials broadly; if you're testing an intervention in human subjects, consult NIH guidance before investing significant effort.
- Provide a clear research strategy with specific aims, significance, and innovation components. Reviewers look for novel approaches to hematology questions and clear scientific rationale.
- Include preliminary data demonstrating feasibility of your proposed research approach. Strong preliminary data significantly improves competitiveness.
- Address your research team's qualifications and institutional support explicitly. Detail how your institution supports your research and what core facilities/resources you'll leverage.
- Budget conservatively and justify all costs carefully. NIH reviewers scrutinize budgets closely, especially for personnel, equipment, and travel; ensure all justify the research plan.
⚠️ Common mistakes
Many applicants underestimate the clinical trial exclusion or misunderstand what NIH considers a clinical trial, leading to desk rejections or unfavorable reviews. Weak preliminary data or lack of proof-of-concept is a common reason for unfavorable scores. Additionally, applicants often fail to adequately address how their innovation builds on or differs from existing hematology research, resulting in lower significance scores.
Similar grants
- OPEN 27-0343-10 FFY27 Local Agency General Non-Enforcement — Illinois Department of Transportation
- ROLLING Annual Agency Threshold Application Applicants for Funding Start Here — Texas City of Austin - Austin Public Health
- CLOSED Virginia’s Black Indigenous and People of Color (BIPOC) Grant – FY26 — Virginia The Virginia Department of Historic Resources
- ROLLING RTAP Grant Program (Rolling) — Virginia Department of Rail and Public Transportation
- ROLLING Rail Industrial Access Grant (RIA) — Virginia Department of Rail and Public Transportation